Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium
K. Rabe, P. Paggiaro, L. Bernabeu, M. Brose, U. M. Goehring, L. Fabbri (Leiden, Netherlands; Pisa, Modena, Italy; Chauny, France; Konstanz, Germany)
Source: Annual Congress 2009 - Treatment of COPD
Session: Treatment of COPD
Session type: Oral Presentation
Number: 1628
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Rabe, P. Paggiaro, L. Bernabeu, M. Brose, U. M. Goehring, L. Fabbri (Leiden, Netherlands; Pisa, Modena, Italy; Chauny, France; Konstanz, Germany). Roflumilast, a PDE4 inhibitor, improves lung function in patients with COPD treated with tiotropium. Eur Respir J 2009; 34: Suppl. 53, 1628
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Roflumilast, an oral, once-daily PDE4 inhibitor, improves lung function and reduces exacerbation rates in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 21s Year: 2004
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Efficacy of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis Source: Annual Congress 2009 - Treatment of COPD Year: 2009
First-dose bronchodilating effect of phosphodiesterase-4 (PDE-4) inhibition by cilomilast (Ariflo) with or without coadministration of salbutamol and/or ipratropium in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis Source: Annual Congress 2009 - Treatment of COPD Year: 2009
The pde4 inhibitor roflumilast provides additional clinical benefit in COPD patients receiving salmeterol Source: Annual Congress 2009 - Treatment of COPD Year: 2009
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
RPL554, an inhaled PDE3/4 inhibitor, causes profound and sustained bronchodilation in healthy volunteers and COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
Cilomilast, a potent, selective inhibitor of phosphodiesterase 4, improves small airway function in patients with chronic obstructive pulmonary disease: results of a 6-month trial Source: Eur Respir J 2001; 18: Suppl. 33, 94s Year: 2001
Roflumilast, a new, orally active, selective PDE4 inhibitor, does not interact with inhaled budesonide Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Formoterol and tiotropium both improve lung function in stable COPD patients, with some additional benefit when given together Source: Eur Respir J 2006; 28: Suppl. 50, 429s Year: 2006
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013
Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD Source: Eur Respir J 2009; 33: 1039-1044 Year: 2009
Effects of procaterol or salmeterol added to maintenance tiotropium therapy on small airway functions in COPD patients Source: Annual Congress 2010 - COPD: management Year: 2010
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study Source: International Congress 2014 – Asthma and COPD management Year: 2014
Roflumilast N-oxide combined with PI3Kδ inhibitor improves the phenotype of early-onset COPD Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016